For the quarter ending 2025-10-31, PMCB made $10,415,438 in revenue. -$8,416,610 in net income. Net profit margin of -80.81%.
| Income Statement | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2024-10-31 |
|---|---|---|---|---|
| Legal and professional | - | - | - | 469,685 |
| Director fees | - | - | - | 138,000 |
| Compensation expense | - | - | - | 283,333 |
| Revenue | 0 | 0 | 0 | - |
| Research and development costs | 141,085 | 95,157 | 122,465 | 97,470 |
| Intangible asset impairment | - | - | 0 | - |
| General and administrative | 1,234,966 | 753,148 | 878,992.5 | 117,572 |
| Total operating expenses | 1,376,051 | 848,305 | 1,001,457.5 | 1,106,060 |
| Loss from operations | -1,376,051 | -848,305 | -1,001,457.5 | -1,106,060 |
| Interest income | 206,387 | 217,793 | 242,783.5 | 382,562 |
| Loss on legal settlement | - | - | -504,750 | - |
| Loss on long term asset | - | - | 0 | - |
| Gain on investment in preferred stock tnf | - | - | 5,348,933.5 | - |
| Change in fair value of investment - tnf | - | -2,839,000 | 4,302,342 | -4,265,000 |
| Change in fair value of warrant liability | -10,474,000 | 243,000 | 3,266,500 | 1,829,000 |
| Change in fair value of derivative liability | 302,000 | 0 | 401,333.333 | 980,000 |
| Change in fair value of warrants - tnf | - | -4,832,000 | -591,921 | - |
| Change in fair value of convertible note receivable - femasys | 392,000 | 912,000 | 130,500 | 435,000 |
| Change in fair value of warrant asset - femasys | -726,000 | -1,215,000 | -428,500 | 276,000 |
| Change in fair value of investment - qcls | -2,371,000 | - | - | - |
| Change in fair value of warrants - qcls | 6,050,000 | - | - | - |
| Gain on legal settlement re-fair value of warrants | 0 | 106,000 | - | - |
| Gain on related party investment - qcls | 2,089,000 | - | - | - |
| Issuance costs series c convertible preferred stock and warrants | -1,234,553 | - | - | - |
| Gain on related party investment - tnf | - | 0 | - | - |
| Loss on issuance of series c convertible preferred stock | -215,000 | - | - | - |
| Unrealized loss on marketable securities | -60,663 | -104,463 | 16,579 | - |
| Other expense | -95 | -121 | 143.5 | -1,062 |
| Total other income and (expense), net | -6,041,924 | -7,511,791 | 4,610,890 | -363,500 |
| Income tax benefit (expense) | - | - | 0 | - |
| Net income (loss) | -7,417,975 | -8,360,096 | 3,609,432.5 | -1,469,560 |
| Preferred stock dividends | 96,639 | 0 | 0 | 443,958 |
| Undistributed income to series b convertible preferred stock | - | - | 742,695 | - |
| Preferred stock accretion | 901,996 | 0 | 0 | 1,045,357 |
| Net income (loss) attributable to common stockholders | -8,416,610 | -8,360,096 | 2,866,737.5 | -2,958,875 |
| Basic income (loss) per share attributable to common stockholders | -1.24 | -1.23 | 0.84 | -0.39 |
| Diluted income (loss) per share attributable to common stockholders | -1.24 | -1.23 | 0.84 | -0.39 |
| Weighted average shares outstanding basic | 6,795,779 | 6,795,779 | -4,086,912.5 | 7,637,034 |
| Weighted average shares outstanding diluted | 6,795,779 | 6,795,779 | -4,086,912.5 | 7,637,034 |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)